[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07639021":3,"trial-entities:NCT07639021":282,"trial-summary:NCT07639021":285},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":25,"interventions":28,"primary_outcomes":47,"secondary_outcomes":52,"sex":60,"minimum_age":61,"maximum_age":17,"healthy_volunteers":15,"eligibility_criteria":62,"std_ages":74,"locations":77,"central_contacts":270,"overall_officials":276,"references":280,"see_also_links":281},"NCT07639021","NN9662-8649","A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity","Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity","RECRUITING","2027-07-12","2026-07","2026-07-10","2026-06-09","Novo Nordisk A\u002FS","INDUSTRY",false,"The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.",null,[19],"Obesity",[],"INTERVENTIONAL","TREATMENT",[24],"PHASE2",{"count":26,"type":27},230,"ESTIMATED",[29,34,38,43],{"type":30,"name":31,"description":32,"armGroupLabels":33},"DRUG","NNC0662-0419","NNC0662-0419 will be administered subcutaneously.",[31],{"type":30,"name":35,"description":36,"armGroupLabels":37},"Semaglutide","Semaglutide will be administered subcutaneously.",[35],{"type":30,"name":39,"description":40,"armGroupLabels":41},"NNC0662-0419 Placebo","Placebo matched to NNC0662-0419 will be administered subcutaneously.",[42],"NNC0662-0419 placebo",{"type":30,"name":44,"description":45,"armGroupLabels":46},"Semaglutide placebo","Placebo matched to semaglutide will be administered subcutaneously.",[44],[48],{"measure":49,"description":50,"timeFrame":51},"Number of gastrointestinal adverse events","Measured as number of events.","From week 0 to week 39",[53,57],{"measure":54,"description":55,"timeFrame":56},"Relative change in body weight","Measured as percentage (%) change.","From week 0 to week 32",{"measure":58,"description":59,"timeFrame":56},"Change in body mass index (BMI)","Measured as kilogram per square meter (kg\u002Fm\\^2).","ALL","18 Years",{"inclusion":63,"exclusion":68,"raw_text":73},[64,65,66,67],"Male or female (sex assigned at birth, inclusive of all gender identities).","Age 18 years or above at the time of signing the informed consent.","Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg\u002Fm\\^2) at screening.","Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.",[69,70,71,72],"Known or suspected hypersensitivity to study intervention(s) or related products.","Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.","Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \\[mmol\u002Fmol\\]) as measured by the central laboratory at screening.","History of type 1 or type 2 diabetes mellitus.","Inclusion Criteria:\n\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Age 18 years or above at the time of signing the informed consent.\n* Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg\u002Fm\\^2) at screening.\n* Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.\n* Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \\[mmol\u002Fmol\\]) as measured by the central laboratory at screening.\n* History of type 1 or type 2 diabetes mellitus.",[75,76],"ADULT","OLDER_ADULT",[78,87,95,102,110,117,124,132,136,145,153,161,169,177,185,193,201,209,217,224,231,239,246,254,262],{"facility":79,"status":8,"city":80,"state":81,"zip":82,"country":83,"geoPoint":84},"Chambliss Clinical Trials, LLC","Montgomery","Alabama","36106","United States",{"lat":85,"lon":86},32.36681,-86.29997,{"facility":88,"status":8,"city":89,"state":90,"zip":91,"country":83,"geoPoint":92},"FDRC","Costa Mesa","California","92627",{"lat":93,"lon":94},33.64113,-117.91867,{"facility":96,"status":8,"city":97,"state":90,"zip":98,"country":83,"geoPoint":99},"Los Angeles Institute for Metabolic Research","Los Angeles","90015",{"lat":100,"lon":101},34.05223,-118.24368,{"facility":103,"status":8,"city":104,"state":105,"zip":106,"country":83,"geoPoint":107},"Encore Medical Research LLC","Hollywood","Florida","33024",{"lat":108,"lon":109},26.0112,-80.14949,{"facility":111,"status":8,"city":112,"state":105,"zip":113,"country":83,"geoPoint":114},"South Broward Research LLC","Miramar","33027",{"lat":115,"lon":116},25.98731,-80.23227,{"facility":118,"status":8,"city":119,"state":105,"zip":120,"country":83,"geoPoint":121},"West Orange Endocrinology","Ocoee","34761",{"lat":122,"lon":123},28.56917,-81.54396,{"facility":125,"status":8,"city":126,"state":127,"zip":128,"country":83,"geoPoint":129},"Cedar-Crosse Research Center","Chicago","Illinois","60607",{"lat":130,"lon":131},41.85003,-87.65005,{"facility":133,"status":8,"city":126,"state":127,"zip":134,"country":83,"geoPoint":135},"Great Lakes Clinical Trials","60640",{"lat":130,"lon":131},{"facility":137,"status":138,"city":139,"state":140,"zip":141,"country":83,"geoPoint":142},"Midwest Inst For Clin Res","NOT_YET_RECRUITING","Indianapolis","Indiana","46260",{"lat":143,"lon":144},39.76838,-86.15804,{"facility":146,"status":8,"city":147,"state":148,"zip":149,"country":83,"geoPoint":150},"L-MARC Research Center","Louisville","Kentucky","40213",{"lat":151,"lon":152},38.25424,-85.75941,{"facility":154,"status":8,"city":155,"state":156,"zip":157,"country":83,"geoPoint":158},"Endo And Metab Cons","Rockville","Maryland","20852",{"lat":159,"lon":160},39.084,-77.15276,{"facility":162,"status":8,"city":163,"state":164,"zip":165,"country":83,"geoPoint":166},"StudyMetrix Research LLC","City of Saint Peters","Missouri","63303",{"lat":167,"lon":168},38.80033,-90.62651,{"facility":170,"status":8,"city":171,"state":172,"zip":173,"country":83,"geoPoint":174},"Great Lakes Medical Research","Westfield","New York","14787",{"lat":175,"lon":176},42.32228,-79.5781,{"facility":178,"status":8,"city":179,"state":180,"zip":181,"country":83,"geoPoint":182},"KDCILM, LLC & Accellacare US, Inc.","Wilmington","North Carolina","28401",{"lat":183,"lon":184},34.23556,-77.94604,{"facility":186,"status":8,"city":187,"state":188,"zip":189,"country":83,"geoPoint":190},"Family Practice Center of Wadsworth Inc.","Wadsworth","Ohio","44281-9236",{"lat":191,"lon":192},41.02561,-81.72985,{"facility":194,"status":8,"city":195,"state":196,"zip":197,"country":83,"geoPoint":198},"UPA Ctr Weight and Eating Dis","Philadelphia","Pennsylvania","19104",{"lat":199,"lon":200},39.95238,-75.16362,{"facility":202,"status":8,"city":203,"state":204,"zip":205,"country":83,"geoPoint":206},"Clinical Res Collaborative","Cumberland","Rhode Island","02864",{"lat":207,"lon":208},41.96677,-71.43284,{"facility":210,"status":8,"city":211,"state":212,"zip":213,"country":83,"geoPoint":214},"Holston Medical Group_Bristol","Bristol","Tennessee","37620",{"lat":215,"lon":216},36.59511,-82.18874,{"facility":218,"status":8,"city":219,"state":212,"zip":220,"country":83,"geoPoint":221},"Holston Medical Group","Kingsport","37660",{"lat":222,"lon":223},36.54843,-82.56182,{"facility":225,"status":8,"city":226,"state":212,"zip":227,"country":83,"geoPoint":228},"Clinical Research Associates","Nashville","37203",{"lat":229,"lon":230},36.16589,-86.78444,{"facility":232,"status":8,"city":233,"state":234,"zip":235,"country":83,"geoPoint":236},"PlanIt Research, PLLC","Houston","Texas","77079",{"lat":237,"lon":238},29.76328,-95.36327,{"facility":240,"status":8,"city":241,"state":234,"zip":242,"country":83,"geoPoint":243},"Pinnacle Clinical Research","San Antonio","78222",{"lat":244,"lon":245},29.42412,-98.49363,{"facility":247,"status":8,"city":248,"state":249,"zip":250,"country":83,"geoPoint":251},"National Clin Res Inc.","Richmond","Virginia","23294",{"lat":252,"lon":253},37.55376,-77.46026,{"facility":255,"status":8,"city":256,"state":257,"zip":258,"country":83,"geoPoint":259},"Rainier Clin Res Ctr Inc","Renton","Washington","98057",{"lat":260,"lon":261},47.48288,-122.21707,{"facility":263,"status":8,"city":264,"zip":265,"country":266,"geoPoint":267},"Isis Clinical Res. Ctr P.S.C.","Guaynabo","00968","Puerto Rico",{"lat":268,"lon":269},18.35745,-66.111,[271],{"name":272,"role":273,"phone":274,"email":275},"Novo Nordisk","CONTACT","(+1) 866-867-7178","clinicaltrials@novonordisk.com",[277],{"name":278,"affiliation":13,"role":279},"Clinical Transparency (dept. 2834)","STUDY_DIRECTOR",[],[],{"nct_id":4,"conditions":283,"biomarkers":284},[19],[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]